Daniel A Pensinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5622445/publications.pdf

Version: 2024-02-01

1305906 1637695 10 703 8 9 citations g-index h-index papers 12 12 12 1063 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A short chain fatty acid–centric view of Clostridioides difficile pathogenesis. PLoS Pathogens, 2021, 17, e1009959.	2.1	23
2	Do Shoot the Messenger: PASTA Kinases as Virulence Determinants and Antibiotic Targets. Trends in Microbiology, 2018, 26, 56-69.	3.5	47
3	Broad detection of bacterial type III secretion system and flagellin proteins by the human NAIP/NLRC4 inflammasome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13242-13247.	3.3	124
4	<i>Listeria monocytogenes</i> cytosolic metabolism promotes replication, survival, and evasion of innate immunity. Cellular Microbiology, 2017, 19, e12762.	1.1	36
5	The Listeria monocytogenes PASTA Kinase PrkA and Its Substrate YvcK Are Required for Cell Wall Homeostasis, Metabolism, and Virulence. PLoS Pathogens, 2016, 12, e1006001.	2.1	60
6	An HD-domain phosphodiesterase mediates cooperative hydrolysis of c-di-AMP to affect bacterial growth and virulence. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E747-56.	3.3	171
7	Selective Pharmacologic Inhibition of a PASTA Kinase Increases Listeria monocytogenes Susceptibility to Î ² -Lactam Antibiotics. Antimicrobial Agents and Chemotherapy, 2014, 58, 4486-4494.	1.4	52
8	The Cyclic Dinucleotide c-di-AMP Is an Allosteric Regulator of Metabolic Enzyme Function. Cell, 2014, 158, 1389-1401.	13.5	174
9	Abstract 1838: Efficacy of ribonuclease QBI-139 in combination with standard of care therapies. Cancer Research, 2012, 72, 1838-1838.	0.4	8
10	Abstract 2573: Combinations of QBI-139, a clinical stage ribonuclease drug., 2011,,.		0